Grünenthal USA Inc.
Partner in Pain Management
Grünenthal USA is a subsidiary of Grünenthal GmbH, an independent, family-owned pharmaceutical company specializing in pain management.
Grünenthal USA partners with other leading pharmaceutical companies to deliver innovative products to patients living with pain.
Grünenthal USA, Inc.
360 Mount Kemble Avenue
Morristown, NJ 07960
Treatment of CRPS
Grünenthal receives Breakthrough Therapy Designation from U.S. FDA for neridronic acid for the treatment of CRPS, a debilitating orphan disease
Grünenthal and Abiogen Pharma, privately held Italian pharmaceutical company with headquarter in Pisa, Italy announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to neridronic acid, an investigational medicine, for the treatment of complex regional pain syndrome (CRPS), a serious, disabling orphan disease. Today, with no FDA- or EMA-approved drug treatments, there is a clear need for effective treatment options to address this significant unmet medical need.